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Abstract
Objectives:
To perform a systematic review to provide rationale for intracoronary (IC) abciximab administration in
patients with ST-segment elevation myocardial infarction (STEMI), to summarize recent studies
comparing IC vs. intravenous (IV) abciximab administration in this setting and to define questions that
need to be answered in future trials determining the optimal abciximab regimen.
Methods:
A search covering the period from January 1993 to June 2011 was conducted by two independent
investigators using MEDLINE, CENTRAL and Google Scholar databases. Proceedings from the scientific
sessions of ACC, AHA, ESC, TCT and EuroPCR were also considered.
Results:
IC administration allows one to obtain a much higher concentration of abciximab than IV injection at the
culprit lesion. Therefore it is hypothesized that IC abciximab administration provides more efficient GP IIb/IIIa
receptor inhibition and more pronounced additional dose-dependent antiplatelet, antithrombotic, and anti-
inflammatory effects when compared to the IV route. Numerous observational and randomized studies
comparing IC vs. IV abciximab in STEMI patients indicated improvement in different surrogate end points
(infarct size, obstruction of coronary microcirculation, ST segment resolution, inflammatory mediators and
markers of platelet activation) related to IC administration. The evidence supporting clinical benefits
associated with IC injection of abciximab comes from one randomized and several non-randomized trials
as most of the studies were underpowered to assess clinical outcomes. No difference in bleeding
complications was observed between IC and IV regimens. Issues that need to be addressed in future
studies include: the use of IC abciximab in combination with thrombectomy, the role of selective delivery
systems, and the necessity of a prolonged IV infusion of abciximab after IC bolus administration.
Conclusions:
An accumulating body of evidence suggests the superiority of IC over IV abciximab administration in STEMI
patients. However, further trials are warranted to establish the optimal strategy of abciximab treatment
in this setting.
Introduction
Primary percutaneous coronary intervention (PCI) with stent implantation is
the mainstay of treatment for ST-segment elevation myocardial infarction
(STEMI)1,2. In order to improve effectiveness of catheter-based reperfusion,
an adjunctive glycoprotein (GP) IIb/IIIa receptor inhibitor, abciximab, was
introduced into clinical practice1,2. Recent European guidelines on myocardial
revascularization recommend therapy with abciximab in STEMI patients with























































evidence of high intracoronary thrombus burden (class of
recommendation IIa, level of evidence A)1. However, the
guidelines do not specify the preferred route of abciximab
administration1,2. Standard abciximab regimen includes
an intravenous (IV) bolus followed by a 12-hour IV
infusion.
The aim of this systematic review is to summarize avail-
able knowledge comparing intracoronary (IC) and IV
abciximab administration in STEMI patients treated
with primary PCI. Moreover, we attempt to define ques-
tions that need to be answered in future trials determining
the optimal abciximab regimen in STEMI patients.
A search covering the period from January 1993 to June
2011 was conducted by two independent investigators
using MEDLINE, CENTRAL and Google Scholar data-
bases. Proceedings from the Scientific Sessions of the
American College of Cardiology (http://www.acc.org),
American Heart Association (http://www.aha.org),
European Society of Cardiology (http://www.escardio.
org), Transcatheter Cardiovascular Therapeutics (http://
www.tctmd.com) and EuroPCR (http://www.europcr.
com) were also considered. The following keywords were
applied: ‘abciximab’, ‘intracoronary administration’,
‘primary PCI’, and ‘ST-elevation myocardial infarction’.
References of retrieved studies were searched manually
for additional studies and reviews. No language restrictions
were applied.
Mechanism of action
Abciximab is a chimeric Fab fragment of the monoclonal
7E3 IgG3 antibody (c7E3 Fab) derived from mouse immu-
nization with human platelets3. It competitively binds to
the GP IIb/IIIa receptor and prevents binding of fibrinogen
and von Willebrand factor to activated platelets, and
therefore blocks the final common pathway for platelet
aggregation3. Abciximab is characterized by a short
plasma half-life due to its rapid binding to exposed GP
IIb/IIIa receptors on the surface of circulating platelets.
This fact results in a strong inhibition of platelet aggrega-
tion, while adhesion and secretion are preserved4,5.
Numerous factors may influence the efficacy of abcix-
imab. Thrombocytosis, basal platelet activation, and ago-
nist stimulation, i.e. thrombin, cause an increase in the
number of available GPIIb/IIIa receptors leading to less
platelet inhibition than expected3,6,7.
Rationale for intracoronary abciximab
administration
Several mechanisms should be considered to explain the
supposed superiority of IC injection of abciximab over the
IV route. Generally, the mechanisms could be divided into
GP IIb/IIIa receptor-dependent and GP IIb/IIIa receptor-
independent. Additional antiplatelet, antithrombotic,
and anti-inflammatory effects of abciximab are dose-
dependent (Figure 1).
Plasma concentration of available abciximab rapidly
decreases after administration due to its rapid binding to
the GP IIb/IIIa receptors. As soon as 10 minutes after bolus
delivery of this compound, more than 80% of the GP
receptors are occupied resulting in a decrease of platelet
aggregation by 80%3–5. Because of the short plasma half-
life of abciximab, its IV administration does not allow one
to obtain a suitable concentration at the culprit lesion and
in the coronary distal bed of the culprit vessel. In contrast
to IV injection, IC route of administration allows one to
obtain a much higher concentration within the coronary
thrombus at the culprit lesion.
Not only does high local concentration of abciximab
decrease platelet activity but it also results in the dissolu-
tion of existing platelet-rich thrombi at the ruptured
plaque and dispersion of newly formed platelet aggregates
reducing distal microembolization8–10. Marciniak et al.8
have shown that abciximab at lower concentrations
(1.5–3.0 mg/ml) prevents further aggregate formation;
however, achieving concentrations 10 mg/ml results in
an extensive dispersion of platelet aggregates.
The c7E3 Fab has properties which impede the forma-
tion and stability of clot structure by inhibition of binding
of the coagulation enzyme, transglutaminase (factor
XIIIa), to platelets11, thereby diminishing crosslinking
of both fibrin strands and a2-anti-plasmin to fibrin9,12.
Inhibition of platelet-induced thrombin generation is
an additional dose-dependent effect of abciximab resulting
in a decreased release of platelet granule containing inhib-
itors of fibrinolysis such as plasminogen activator inhibi-
tor-1 and a2-anti-plasmin3.
Concentrations of abciximab that produce complete
platelet disaggregation also inhibit thrombin–antithrom-
bin complex formation, prothrombin fragment F1þ2 gen-
eration, platelet-derived growth factor and platelet factor 4
release, as well as incorporation of thrombin into clots, and
microparticle formation13.
Furthermore, increased porosity of thrombus caused by
c7E3 Fab allows penetration of endogenous fibrinolytic
agents into the clot, thereby promoting more rapid and
extensive spontaneous thrombolysis10.
IC administration may also enhance the non-GP
IIb/IIIa properties of abciximab that are mainly based on
complex anti-inflammatory interactions. In contrast to
other GP IIb/IIIa inhibitors, abciximab is a non-selective
GP IIb/IIIa receptor antagonist. It also binds to vitronectin
(avß3, CD51/CD61) expressed on endothelial and smooth
muscle cells, monocytes, polymorphonuclear leukocytes,
and T lymphocytes3,14,15 and demonstrates affinity for
the integrin Mac-1 (aMß2, CD11b/CD18) found on
monocytes and neutrophils16,17. Interactions of abciximab
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with Mac-1 leukocyte receptors and saVß3 vitronectin
receptors on endothelial and smooth muscle cells are pos-
tulated to decrease the inflammatory response in the endo-
thelium of the injured vessel, hence reducing further
platelet aggregation. Reduction of smooth muscle cells
migration preventing intimal hyperplasia on abciximab
therapy was demonstrated in animal models3,18. In fact,
a reduction in the rate of target vessel revascularizations
in favour of abciximab was observed in the EPIC (16.5 vs.
22.3%; p¼ 0.007)19 and the ISAR-SWEET (23.2 vs.
30.4%; p¼ 0.03)20 trials. However, it was not confirmed
in other clinical trials using prolonged GP IIb/IIIa receptor
inhibition after PCI3,21. Vitronectin receptors on acti-
vated platelets have been implicated in both platelet adhe-
sion to osteopontin present in atherosclerotic plaque and
platelet-mediated thrombin generation3,22. Thus, abcixi-
mab provides a more potent inhibition of platelets due to
a ‘dual’ receptor blockade (GP IIb/IIIa and avß3).
The leukocyte integrin Mac-1 binds heterogeneous
ligands including inter-cellular adhesion molecule 1
(ICAM-1), fibrin, fibrinogen and factor X. Several studies
demonstrated that the Mac-1 inhibition by abciximab is
associated with interruption of the adhesive and migratory
capability of leukocytes and reduction of tissue injury23–26.
The interaction between c7E3 Fab and the integrin Mac-1
blocks the adhesion of monocytes to ICAM-1 and fibrin27
and decreases thrombus deposition at the site of arterial
injury by inhibiting the binding of factor X and its activa-
tion to factor Xa28.
All these mechanisms may result in subsequent
improvement in clinical outcome in patients treated
with IC bolus of abciximab as compared to IV administra-
tion due to reduced reperfusion injury and a higher degree
of myocardial salvage.
Overview of current status
Theoretical advantages of IC abciximab regimen over
the IV route have led to clinical trials whose results with
possible interpretations are summarized below.
Clinical studies assessing benefits of IC over IV
abciximab administration in terms of surrogate
endpoints
A clinically relevant improvement in myocardial reperfu-
sion as assessed by myocardial blush grade (MBG 2 or 3: 76
vs. 67%; p¼ 0.022) was observed in the CICERO trial29 in
STEMI patients randomized to IC bolus of abciximab
given directly after thrombectomy (n¼ 271) as compared
to IV bolus administration (n¼ 263). This finding was in
line with approximately 30% smaller infarct size in the IC
group than in IV group as assessed by plasma concentration
of creatine kinase (median 1214 [interquartile range 488–
2184] vs. median 1746 [interquartile range 733–3383] U/L;
p¼ 0.008), creatinine kinase-MB (median 154 [interquar-
tile range 62–262] vs. median 232 [interquartile range
90–400] U/L; p¼ 0.003), and cardiac troponin T
(median 3.03 [interquartile range 0.95–5.81] vs. median
4.36 [interquartile range 1.43–8.56] mg/L; p¼ 0.008). In
contrast to some other studies30–32, it was not confirmed
blockade of IIb/IIIa glycoprotein
Inhibition of binding of factor XIIIa to platelets
Inhibition of fibrinogen and factor X binding
Inhibition of monocyte adhesion on ICAM-1
Inhibition of MAC-1 mediated activation of factor X
blockade of vitronectin receptor and adhesion to osteopontin























Figure 1. Mechanisms of abciximab action. GP IIb/IIIa – glycoprotein IIb/IIIa; ICAM-1 – intercellular adhesion molecule 1; vWF – von Willebrand factor..
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by the differences in complete ST-segment resolution
(64 vs. 62 %; p¼ 0.562). The authors did not find any
difference regarding ischemic events (major adverse car-
diac events: 5.5 vs. 6.1%, p¼ 0.786) and bleeding compli-
cations (major bleedings: 3.7 vs. 3.4%; p¼ 0.867 and
minor bleedings: 7.7 vs. 6.8%; p¼ 0.688, respectively) in
the compared groups during 30-day follow-up. It is very
likely that the benefit of intracoronary administration on
myocardial reperfusion was offset by a relatively low clin-
ical risk profile of patients and the routine use of thrombus
aspiration in the study. Furthermore, although this study
was the largest randomized trial conducted in this field, it
had insufficient power to detect differences in ischemic
and bleeding events29.
Antagonists of GP IIb/IIIa have been reported to reduce
concentration of soluble CD40 ligand (sCD40L) in vitro3,33
and in vivo34. CD40L regarded as a unique molecule link-
ing inflammation, thrombosis, and restenosis is secreted
by circulating aggregates of platelets and leukocytes35.
sCD40L binds to platelets via an aIIb3-dependent mech-
anism and triggers further platelet activation36,37.
Dominguez-Rodriguez et al.38 compared the effects of IC
(n¼ 25) vs. IV (n¼ 25) abciximab bolus administration
on sCD40L levels in patients with STEMI undergoing
thrombus aspiration during primary PCI. In the IC
group, abciximab bolus was administrated after thrombect-
omy to improve abciximab penetration and allow its high
concentration in the target region. IC abciximab admin-
istration was associated with a higher reduction in sCD40L
concentration compared to IV administration
(73.04 12.21 vs. 99.92 25.89 pg/mL; p50.001). This
finding might be explained by the higher local levels of
abciximab in the IC group, which may facilitate the diffu-
sion of antibodies to platelets inside the flow-limiting
thrombus, thus resulting in enhanced dissolution of
thrombi and microemboli and further downstream of
abciximab in the microcirculation. No-reflow phenome-
non was observed in 12 and 32% of patients in the IC and
IV groups (p¼ 0.08), respectively. Moreover, infarct size,
as assessed by the peak of troponin I, was significantly
lower in patients treated with IC as compared with
IV bolus of abciximab (70 32 vs. 95 27 pg/mL;
p¼ 0.004). This finding was associated with a trend
towards improved myocardial perfusion as assessed by
ST-segment resolution measured as a continuous variable
(median 79.8 [interquartile range 64.7–100] vs. median
72.0 [interquartile range 43.2–85.5] %; p¼ 0.09). As antic-
ipated, due to the limited number of patients, no signifi-
cant differences were detected in terms of mortality,
re-infarction, need for urgent or any revascularization at
30-day follow-up38. Finally, the authors hypothesized on
a synergistic effect between thrombus aspiration and IC
abciximab administration in patients with STEMI38.
The aim of the randomized study published by Thiele
et al.32 was to assess the effects of IC vs. IV abciximab bolus
administration followed by a 12-hour IV infusion on the
occurrence of no-reflow phenomenon and infarct size
assessed by contrast-enhancement magnetic resonance
imaging. In the IC group, bolus administration was recom-
mended after infarct-related artery recanalization by the
PCI wire before balloon dilatation to allow high abciximab
concentration in the target region. Thrombectomy was
not used in this study. The infarct size evaluated by mag-
netic resonance imaging was significantly smaller after
IC (n¼ 77) compared with IV (n¼ 77) abciximab bolus
administration (median 15.1 [interquartile range 6.1–25.2]
vs. median 23.4 [interquartile range 13.6–33.2] %;
p¼ 0.01). Furthermore, there was a significantly lower
infarct size in the IC group as assessed by the area under
the curve of creatine kinase release (median 575 [inter-
quartile range 359–863] vs. median 736 [interquartile
range 416–1304]mmol L1 h1; p¼ 0.007).
Similarly, the extent of early microvascular obstruction
was smaller in the IC than the IV group (median 2.1 [inter-
quartile range 0.0–5.1] vs. median 4.3 [interquartile range
0.35–13.2]%; p¼ 0.06) and late (median 0.4 [interquartile
range 0.0–1.8] vs. median 1.6 [interquartile range 0.03–
5.0] %; p¼ 0.04). ST-segment resolution expressed as a
continuous variable was also significantly more pro-
nounced in the IC abciximab group (median 77.8 [inter-
quartile range 66.7–100] vs. median 70.0 [interquartile
range 45.2–83.5] %; p¼ 0.006). However, left ventricular
ejection fraction and end-diastolic and end-systolic
volume indexes as well as thrombolysis in myocardial
infarction (TIMI) flow and TIMI perfusion grades did
not differ between the compared groups. In contrast to
ECG assessment reflecting improved tissue perfusion,
TIMI flow and perfusion grades might not be sensitive
enough to detect differences in the very early setting
after abciximab bolus administration32. Patients with ante-
rior myocardial infarction, those undergoing reperfusion
44 hours after symptom onset, as well as patients with
impaired TIMI flow and perfusion grades after PCI had
greater benefit from IC vs. IV abciximab bolus administra-
tion32. Improved myocardial perfusion in patients treated
with IC abciximab resulted in better 30-day clinical out-
come of borderline significance. The composite major
adverse cardiac event (cardiac deaths, nonfatal reinfarc-
tions, need for target vessel revascularization, new onset
congestive heart failure) rate was 5.2% after IC and 15.6%
after IV abciximab administration (relative risk 0.33;
95% confidence interval [CI] 0.09–1.05; p¼ 0.06)32.
These data are in line with observations published by
Romagnoli et al.39 They performed a prospective assess-
ment of angiographic effect of IC vs. IV abciximab bolus
in patients with acute coronary syndromes undergoing
urgent PCI. The corrected TIMI frame count (CTFC)
significantly decreased immediately after IC abciximab
administration in the culprit vessel (48 37 to 33 30;
p¼ 0.001) but not in the non-culprit one (16 7 to
Current Medical Research & Opinion Volume 27, Number 11 November 2011























































16 7; p¼ 0.68). In contrast, this improvement did not
occur after IV delivery. Interestingly, the acute decrease in
CTFC observed after IC administration of abciximab was
present in 37% of patients with vs. 4% of those without
a visible thrombus (p¼ 0.008)39.
Bellandi et al.40 reported results obtained in a popula-
tion of consecutive patients with a first STEMI and
infarct-related artery TIMI flow 0-1 undergoing primary
PCI, randomly assigned to the IC (n¼ 22) or IV (n¼ 23)
abciximab administration. Before starting PCI, patients
received a bolus of abciximab either IC through a dual-
lumen catheter (Multifunctional Probing) positioned
below the occlusion, or IV. Bolus was followed by a
12-hr abciximab infusion in both groups. All patients
underwent single photon emission computed tomography.
Abciximab given IC resulted in a higher degree of myo-
cardial salvage (20.4 8.9 vs. 11.0 7.5% of left ventri-
cle; p50.0001) than the IV administration. This benefit
was mainly related to a substantial reduction in the final
infarct size (13.5 11.2 vs. 21.4 12.7% of left ventricle;
p50.044), leading to an improvement in left ventricular
ejection fraction (53.3 9.5 vs. 46.3 10.7%; p50.035)
at 1 month after PCI40.
A single-center prospective randomized trial aimed to
evaluate the efficacy and safety of IC (n¼ 72) vs. IV
(n¼ 65) administration of the abciximab bolus in patients
undergoing coronary angioplasty with stent implantation
was performed by Galache Osuna et al.41. The study
included 57 patients with acute myocardial infarction
and 80 with unstable angina. Considerably less post-
procedural myocardial damage as assessed by troponin I
was observed in the IC bolus group (an increase more
than five times the upper limit for normal values: 26 vs.
51%; p50.05). Nevertheless, the clinical follow-up at
1 year did not reveal any difference in the incidence of
major adverse cardiac events (8.5% in the IC group vs.
6.2% in the IV group; p¼ ns) and major bleedings
(detailed data not provided by the authors)41.
The equivalence between abciximab bolus-only and
abciximab bolus followed by a 12-hr infusion in a wide
spectrum of patients after PCI was shown in the EASY
trial42. However, it should be underlined that, according
to the study protocol, patients with STEMI were excluded.
A post hoc analysis of this trial was performed by Bertrand
et al.43. Out of 1005 randomized patients undergoing a
transradial coronary stent implantation, 208 received an
IC and 797 received an IV abciximab bolus. Compared to
IV abciximab administration, IC abciximab was not
associated with less cardiac biomarkers release nor better
clinical outcomes after uncomplicated transradial PCI43.
Platelet aggregation inhibition (PAI) of 95% is asso-
ciated with improved outcomes after PCI and GP IIb/IIIa
inhibitor treatment. In the EASY-MI Study44 105 STEMI
patients who had been referred for primary PCI within
6 hours of symptom onset were randomized to receive IC
(n¼ 53) or IV (n¼ 52) abciximab bolus at a standard
(0.25 mg/kg) or high dose (0.30 mg/kg). The primary
end point of the trial was PAI measured at 10 minutes
after the bolus of abciximab. The secondary end points
included acute and 6-month outcomes using angiographic
parameters, cardiac biomarkers, cardiovascular magnetic
resonance imaging, and clinical variables. Aspiration
thrombectomy was performed in 40% of the IC group
patients and in 44% of the patients treated with IV
bolus. At 10 minutes after the bolus, there was no differ-
ence in the proportion of patients with PAI 95% in the
IC vs. IV (53 vs. 54%; p¼ 1.00) and the high-dose vs.
standard-dose bolus groups (56 vs. 51%; p¼ 0.70). The
TIMI flow grade and necrosis size, as assessed by cardiac
biomarker measurement, were similar across the compared
groups. The incidence of myocardial blush grade 2 and 3
was slightly higher in the IC group than in the IV group
(88 vs. 75%, respectively; p¼ 0.13). Moreover, neither a
higher dose nor IC abciximab bolus were associated with
improved acute or late results compared to the standard IV
dosing and administration44.
Studies relating IC abciximab to improvement
in clinical outcomes
A nonrandomized, retrospective comparison of the effi-
cacy of IC (n¼ 294) and IV (n¼ 109) bolus of abciximab
followed by 12 hours of IV infusion in patients with acute
myocardial infarction (n¼ 305) or unstable angina
(n¼ 92) was published by Wöhrle et al.45. At 30 days of
follow-up, the incidence of major adverse cardiac events
(MACE) including death, myocardial infarction, and
urgent revascularization was significantly lower in patients
with intracoronary compared with intravenous adminis-
tration of abciximab (10.2 vs. 20.2%; p50.008). There
was a significant interaction between the preprocedural
TIMI flow, the application of abciximab, and the inci-
dence of MACE. In patients with preprocedural TIMI
0/1 flow, MACE occurred significantly less often after
IC abciximab, compared with the IV use (11.8 vs.
27.5%; p50.002). In contrast, the prevalence of MACE
did not differ between the treatment strategies in patients
with preprocedural TIMI 2/3 flow45. The authors did not
report on bleeding events.
Another retrospective study published by Kakkar et al.46
showed similar findings. In an unselected population of
patients (n¼ 173; 31 patients with acute myocardial
infarction) undergoing coronary stenting and abciximab
administration, IC bolus (n¼ 101) injection was associ-
ated with a significantly lower 6-month composite end-
point of death or myocardial infarction (5.9 vs. 13.9%;
p50.04) as compared to patients treated with IV bolus
(n¼ 72). Major bleedings according to the TIMI defini-
tion were also less frequent in the IC group. However, the
Current Medical Research & Opinion Volume 27, Number 11 November 2011























































difference did not reach statistical significance (4.0 vs.
8.3%; p¼ 0.32). In both groups bolus was followed by a
12-hr IV infusion of abciximab46.
In a single-site, randomized study Iversen et al.47
assessed the efficacy and safety of IC (n¼ 185) vs. IV
(n¼ 170) bolus of abciximab administered during primary
PCI in STEMI patients and followed by a 12-hour IV infu-
sion. Within 30 days after randomization significantly
better results were observed in the IC group in terms of
mortality (1.1 vs. 5.3%; p¼ 0.02), target vessel revascular-
ization (3.8 vs. 9.4%; p¼ 0.03) and the composite
end-point (target vessel revascularization, myocardial
infarction or death: 7.6 vs. 19.4%; p¼ 0.001). Since the
total dose of abciximab was identical irrespective of the
route of administration, as expected no differences con-
cerning the safety of treatment (major and minor bleeding
complications defined according to the study protocol: 1.6
vs. 2.4%; p¼ 0.62 and 9.7 vs. 14.1%; p¼ 0.20, respec-
tively) between the groups were seen47.
In the absence of results from large multicenter, ran-
domized trials, a meta-analysis may provide clinically
important information comparing results of two different
strategies of treatment with abciximab – IC vs. IV. Data
obtained from five randomized trials and three retrospec-
tive studies were analyzed by Hansen et al.48. The total
number of 2301 patients, including 997 with STEMI,
were incorporated in this meta-analysis. Pooled data anal-
ysis demonstrated significantly reduced mortality (odds
ratio 0.57, 95% CI 0.35–0.94; p¼ 0.028), and a trend
toward a reduction of major adverse cardiac events (odds
ratio 0.62, 95% CI 0.38–1.03; p¼ 0.066) during up to
12 months of follow-up with IC vs. IV abciximab. A sig-
nificant MACE reduction was observed after 1 month of
follow-up exclusively in studies composed of patients with
STEMI (p50.001)48. Unfortunately, the authors did not
assess bleeding complications.
Open questions
Results obtained in studies comparing IC and IV adminis-
tration of abciximab in STEMI patients stand consistently
in favor of the IC bolus in all studies29,32,38,40,45–47 except
one44 (Table 1). Important limitations of these studies
should be underlined: not all of the studies were random-
ized, all included relatively low numbers of patients, all
were single-center, only some of them showed improve-
ment in clinical outcome, while others revealed the supe-
riority of IC administration only by assessment of different
surrogate end points (infarct size assessed with biomarkers
or imaging modalities, obstruction of coronary microcircu-
lation evaluated by angiography or contrast-enhancement
magnetic resonance, ST-segment resolution, markers of
platelet activation), all were underpowered to assess
bleeding complications as well as various bleeding defini-
tions were applied.
In contrast to the superiority of IC vs. IV administration
in high-risk STEMI patients, the relative gain in the low
risk population is questionable.
Nevertheless, the answer to the question ‘which way of
abciximab administration is better?’ seems to favor the IC
route. However, before reaching a definitive conclusion
further adequately powered, multi-center, randomized
trials are warranted. Moreover, our knowledge concerning
the optimal strategy of abciximab administration in
STEMI patients is incomplete.
Several clinically relevant questions still remain
unanswered:
 Does IC abciximab administration provide a better
safety profile than the IV route?
 Can results of IC abciximab administration through
the guiding catheter be further improved by the use
of more selective delivery systems?
 Should IC abciximab be combined with
thrombectomy?
 If so, should IC abciximab be administered before or
rather after thrombectomy?
 Should the bolus of abciximab be followed by a pro-
longed IV infusion?
Below we discuss available knowledge regarding unan-
swered issues listed above and present design of several
ongoing trials addressed to overcome some shortcomings
of the previous studies.
Assessment of efficacy and safety profile
of IC vs. IV abciximab administration
Limited number of participants and clinical events in com-
pleted studies precludes final conclusions regarding the
safety and efficacy profile of IC vs. IV abciximab adminis-
tration in the STEMI patients. Therefore the AIDA
STEMI study49 was designed. It is a randomized, multi-
center, open-label, controlled trial designed to test
whether IC abciximab bolus administration in comparison
to standard IV application improves the clinical outcome
of STEMI patients undergoing primary PCI. According to
the study protocol a bolus of abciximab is followed by
an IV infusion for 12 hours. In all patients, PCI of the
infarct-related artery is performed according to standard
procedures and the use of thrombectomy is strongly rec-
ommended in both groups, particularly in lesions with a
high thrombus burden. The route of abciximab bolus deliv-
ery is the only difference between the compared groups.
Abciximab bolus should be delivered directly after pene-
tration of the culprit lesion with the PCI guiding wire to
allow for high local concentrations of the antithrombotic
agent at the thrombus and distal myocardium. No specific
Current Medical Research & Opinion Volume 27, Number 11 November 2011
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infusion balloons or perfusion catheters are used. The pri-
mary efficacy end point of AIDA STEMI is the composite
of all-cause mortality, recurrent myocardial infarction, or
new onset congestive heart failure within 90 days of ran-
domization. The primary safety outcome assessment will be
major bleeding. The study population will consist of 1912
STEMI patients enrolled at 30 centers in Germany.
Results of this trial are expected soon49.
Selective delivery systems
A bolus of abciximab is usually administered through the
guiding catheter into the infarct-related artery. However,
this method of administration may not provide an optimal
contact between the plaque components and abciximab,
with the latter rapidly washed out by the coronary flow.
Prati et al.50 tested the effectiveness of local abciximab
delivery to the site of IC thrombus vs. IC bolus infusion
in patients with acute coronary syndromes undergoing PCI
in the COCTAIL Study. For local IC delivery of abcixi-
mab a dedicated perfusion catheter – ClearWay RX Local
Therapeutic Infusion Catheter (ClearWay, Atrium
Medical Corp, Hudson, NH, USA) was applied.
ClearWay is a low-profile, rapid-exchange therapeutic
infusion catheter, indicated for localized perfusion of var-
ious diagnostic and therapeutic agents into the coronary
and peripheral vasculature. The ClearWay therapeutic
infusion catheter enables local drug delivery to reach
approximately a 500-fold greater drug concentration vs.
systemic delivery. Despite a low number of patients
included (n¼ 50), very encouraging results were obtained.
Significantly higher reduction of thrombus (mean percent-
age change of the thrombus score: 33.8 vs. 3.9%;
p¼ 0.002) and superior corrected TIMI frame count
(15.3 10.2 vs. 21.1 9.9; p¼ 0.049) were observed
among patients of the local delivery group as compared
with those of the IC infusion group. These benefits trans-
lated into better clinical outcome. Procedure-related myo-
cardial infarction was observed in 10 and 43% (p¼ 0.018),
while MACE at 1 year were observed in 5.9 and 27.2% of
patients in the local delivery and intracoronary infusion
groups, respectively (p¼ 0.046). These results strongly
suggest that the use of the dedicated perfusion catheter
leads to higher concentrations of abciximab within the
thrombus, allowing for an additional antiplatelet, antith-
rombotic, and anti-inflammatory effect50.
The effectiveness of an IC bolus of abciximab locally
delivered using the ClearWay RX Local Therapeutic
Infusion Catheter is also evaluated in the ongoing
IC-Clearly Study51. The purpose of this randomized,
open-label, multicenter trial is the comparison of a locally
delivered bolus of abciximab with an IV bolus in STEMI
patients with an angiographically visible thrombus
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size assessed by cardiac magnetic resonance. Clinical out-
comes will be assessed for each patient at hospital dis-
charge and at 30-day follow-up51.
Recently preliminary results of the Crystal AMI trial
have been presented52. In this single-center, prospec-
tively randomized study the hypothesis that local IC
delivery with ClearWay RX Local Therapeutic Infusion
Catheter leads to more pronounced ST resolution, higher
MBG, improved TIMI flow and smaller infarct size than
IV abciximab in STEMI patients treated with primary
PCI was tested. The majority of patients received
manual thrombus aspiration in each study arm (65%).
Because of a low number of patients enrolled in the
study (n¼ 50), surrogate instead of clinical end points
were chosen. Furthermore, the study was a pilot proof
of concept trial, not powered to show statistical differ-
ences. Super-selective IC delivery of abciximab facili-
tated by the ClearWay catheter was safe and effective,
and resulted in a better final TMI flow (TIMI 3: 96 vs.
82%; p¼ 0.30), higher MBG score (MBG of 3: 72 vs.
52%; p¼ 0.15), and more pronounced ST-segment reso-
lution (80 vs. 70%; p¼ 0.89). Data regarding infarct size
have not been presented so far.
Taking into account the reduction of the thrombus
burden related to IC abciximab administration and the
fact that this effect is probably even more pronounced by
super-selective local delivery, such therapy may further
facilitate the direct stenting approach. Direct stenting
has been demonstrated to improve myocardial perfusion
and to reduce risk of death and chronic heart failure in
STEMI patients initially treated with fibrinolysis53. Thus it
could be hypothesized that a greater use of primary stenting
may be an additional positive effect of this therapy.
The application of thrombectomy in
patients treated with IC abciximab
The question whether thrombus aspiration combined
with local glycoprotein IIb/IIIa administration exerts a
synergistic effect to reduce infarct size in STEMI patients
undergoing primary PCI has not been answered yet.
INFUSE-AMI is an ongoing, multicenter, open-label,
controlled, single-blind randomized study testing the
hypothesis that IC administration of an abciximab
bolus with or without thrombus aspiration before stent
implantation compared to no infusion with or without
thrombus aspiration reduces infarct size among patients
undergoing primary PCI for anterior STEMI who are
treated with bivalirudin54. For IC administration the
ClearWay RX Local Therapeutic Infusion Catheter is
used. The study population consists of patients with ante-
rior STEMI and an occlusion of proximal or mid-left
anterior descending artery with TIMI 0, 1, or 2 grade
flow undergoing primary PCI. Subjects are randomized
to one of the following four arms: (1) local IC infusion
of abciximab after thrombus aspiration, (2) local IC infu-
sion of abciximab, without thrombectomy, (3) thrombus
aspiration without IC abciximab, or (4) without IC
abciximab and without thrombectomy. The primary
end point is infarct size (percentage of total left ventric-
ular mass) at 30 days measured by cardiac magnetic res-
onance imaging. Other secondary end points include
microvascular obstruction assessed with cardiac magnetic
resonance imaging at 5 days, ST-segment resolution,
angiographic myocardial perfusion, thrombus burden,
angiographic complications, and clinical events through
1-year follow-up54.
The most beneficial sequence of administration of IC
bolus of abciximab – i.e. before or after thrombectomy –
should be defined in future studies.
The necessity of a prolonged IV infusion of
abciximab after IC bolus administration
Results of the EASY trial proving the equivalence between
abciximab bolus-only and abciximab bolus followed by a
12-h infusion in patients with unstable or stable angina
treated with PCI are not automatically valid for the
STEMI population42. From the pathophysiological point
of view the potent antiplatelet action of abciximab is more
important in STEMI, as the thrombus burden is usually
much higher as compared to both stable and unstable
angina. Moreover, prolonged IV infusion may be of
higher importance in patients treated with IV bolus
because of a more potent abciximab action due to its
higher concentration in the culprit vessel with IC vs. IV
bolus. Thus the question concerning the necessity of a
prolonged IV infusion subsequent to the initial bolus of
abciximab in STEMI patients is still waiting for the final
answer.
Conclusions
An accumulating body of evidence suggests the superiority
of IC over IV abciximab administration in STEMI patients
treated with primary PCI. However, further trials are
warranted to establish the optimal strategy of abciximab
treatment in this setting.
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